Barriers to antibody therapy in solid tumors, and their solutions

Radioimmunotherapy with an 211 At‐labeled anti‐tissue factor antibody protected by sodium ascorbate

(2021) Hiroki Takashima et al.   CANCER SCIENCE

Unlocking the potential of antibody–drug conjugates for cancer therapy

(2021) Joshua Z. Drago et al.   Nature Reviews Clinical Oncology

Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus

(2020) Sara Calzavarini et al.   BLOOD

Cancer stromal targeting therapy to overcome the pitfall of EPR effect

(2020) Yasuhiro Matsumura   ADVANCED DRUG DELIVERY REVIEWS

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

(2019) Johann S de Bono et al.   LANCET ONCOLOGY

Targeting anticoagulant protein S to improve hemostasis in hemophilia

(2018) Raja Prince et al.   BLOOD

Tumor stroma–targeted antibody-drug conjugate triggers localized anticancer drug release

(2018) Christopher Szot et al.   JOURNAL OF CLINICAL INVESTIGATION

Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor

(2018) Ryo Tsumura et al.   JOURNAL OF CONTROLLED RELEASE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bispecific antibodies for cancer therapy: A review

(2018) Anuradha Krishnamurthy et al.   PHARMACOLOGY & THERAPEUTICS

Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin

(2018) Hirobumi Fuchigami et al.   Scientific Reports

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted radionuclide therapy in combined-modality regimens

(2017) Martin R Gill et al.   LANCET ONCOLOGY

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

(2017) Toshihiko Doi et al.   LANCET ONCOLOGY

Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix

(2016) Rémy Gébleux et al.   INTERNATIONAL JOURNAL OF CANCER

Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts

(2015) Yoshikatsu Koga et al.   INTERNATIONAL JOURNAL OF CANCER

An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors

(2013) E. C. W. Breij et al.   CANCER RESEARCH

Discovery of an uncovered region in fibrin clots and its clinical significance

(2013) Yohei Hisada et al.   Scientific Reports

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer stromal targeting (CAST) therapy

(2011) Yasuhiro Matsumura   ADVANCED DRUG DELIVERY REVIEWS

The relationship between tissue factor and cancer progression: insights from bench and bedside

(2011) Y. W. van den Berg et al.   BLOOD

New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots

(2011) Masahiro Yasunaga et al.   CANCER SCIENCE

The inhibition of pancreatic cancer invasion-metastasis cascade in both cellular signal and blood coagulation cascade of tissue factor by its neutralisation antibody

(2011) Yohei Saito et al.   EUROPEAN JOURNAL OF CANCER

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE